Elicera Therapeutics AB (DE:8E8)

FRANKFURT:8E8

8E8

Elicera Therapeutics AB

RESEARCH TOOLSreports

Elicera Therapeutics AB (8E8) Price & Analysis

0 Followers

8E8 Stock Chart & Stats

€0.47

€0.03(20.86%)

At close: Jan 08 4:00 PM EST

€0.47

€0.03(20.86%)

Day’s Range― - ―

52-Week Range€0.19 - €0.67

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€16.46M

Enterprise Value€132.32M

Total Cash (Recent Filing)€24.85M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.41

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.41

Shares Outstanding72,803,314

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)10.19

Price to Sales (P/S)0.00

P/FCF Ratio-11.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.05

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Capital StructureZero debt materially lowers solvency risk for an R&D-stage biotech, preserving flexibility to fund clinical programs via equity or partnerships. This structural conservatism reduces bankruptcy risk and supports multi-year development timelines common in cell/gene therapy.

High Gross Margins On Revenue EpisodesWhen revenue was generated, gross profit margins were strong, implying the underlying products/services can scale with favorable unit economics. Durable high gross margins support long-term profitability once fixed R&D and SG&A are controlled or outsourced.

Strategic Focus On Next‑Gen Immuno‑OncologyA technology-rich pipeline in cell/gene and CAR T therapies targets structurally growing immuno-oncology markets. Proprietary platform work (iTANK) can create durable differentiation, licensing and partnership optionality if clinical progress validates mechanisms.

Bears Say

Persistent Cash BurnRecurring negative operating and free cash flow implies structural reliance on external financing to sustain R&D. Over the medium term this increases dilution risk and constrains strategic choices unless clinical milestones trigger partnership or non-dilutive funding.

Shrinking Equity CushionA materially reduced equity base weakens the balance sheet buffer against further losses and limits borrowing or favorable deal leverage. This structural erosion elevates risk of dilution and reduces downside protection for longer development cycles.

Revenue Volatility And Commercial VisibilityLarge swings to zero reported revenue indicate weak or non-recurring commercial traction and heavy dependence on milestone-driven receipts. This lack of predictable revenue undermines self-funding prospects and makes long-term planning and valuation highly dependent on trial outcomes.

8E8 FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?

Elicera Therapeutics AB lowest stock price was €0.19 and its highest was €0.67 in the past 12 months.

What is Elicera Therapeutics AB’s market cap?

Elicera Therapeutics AB’s market cap is €16.46M.

When is Elicera Therapeutics AB’s upcoming earnings report date?

Elicera Therapeutics AB’s upcoming earnings report date is Aug 21, 2026 which is in 69 days.

How were Elicera Therapeutics AB’s earnings last quarter?

Elicera Therapeutics AB released its earnings results on Apr 21, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.009.

Is Elicera Therapeutics AB overvalued?

According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elicera Therapeutics AB pay dividends?

Elicera Therapeutics AB does not currently pay dividends.

What is Elicera Therapeutics AB’s EPS estimate?

Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elicera Therapeutics AB have?

Elicera Therapeutics AB has 72,803,314 shares outstanding.

What happened to Elicera Therapeutics AB’s price movement after its last earnings report?

Elicera Therapeutics AB reported an EPS of -€0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.677%.

Which hedge fund is a major shareholder of Elicera Therapeutics AB?

Currently, no hedge funds are holding shares in DE:8E8

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several drug candidates, including ELC-100, which is currently undergoing Phase I/II trials for neuroendocrine tumors. The company is also advancing ELC-201 and ELC-401 through preclinical development, with ELC-401 specifically targeting glioblastoma multiforme (a form of brain tumor). Furthermore, Elicera is developing ELC-301, a CAR T-cell therapy intended for the treatment of Non-Hodgkin's B-cell lymphoma. A cornerstone of their work is the iTANK technology platform, engineered to enhance the efficacy of their CAR T-cell therapies and stimulate killer T-cells to attack cancerous cells.